Pneumococcal polysaccharide vaccination for adults: New perspectives for Europe

Expert Review of Vaccines

Volumn 10, Issue 8, 2011, Pages 1143-1167

  Fedson, David S ^a   Nicolas Spony, Laurence ^b   Klemets, Peter ^c   Van Der Linden, Mark ^d   Marques, Agostinho ^e   Salleras, Luis ^f   Samson, Sandrine I ^b  

^a Sanofi Pasteur MSD ^*  (France)

^b SANOFI PASTEUR   (France)

^c Porvoo Hospital   (Finland)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e University of Porto   (Portugal)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

adults; cost effectiveness; effectiveness; elderly; immunogenicity; invasive pneumococcal diseases; pneumococcal conjugate vaccines; pneumococcal infections; pneumococcal polysaccharide vaccines pneumonia; vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; HUMAN; KIDNEY DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PHARYNX DISEASE; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEROTYPE; STAPHYLOCOCCUS AUREUS;

EID: 80052069265     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.99     Document Type: Review

References (158)

1. World Health Organization. 23-valent pneumococcal polysaccharide vaccine. Position paper. Wkly Epidemiol. Rec. 83 (42), 373-384 (2008)
2. Fedson DS, Musher DM. Chapter 22. Pneumococcal polysaccharide vaccine. In:Vaccines. 4th Edition . Plotkin SA, Orenstein WA (Eds). Saunders Elsevier, Philadelphia, PA, USA, 529-588 (2004)
3. Jackson LA, Neuzil KM. Chapter 24. Pneumococcal polysaccharide vaccines. In:Vaccines. 5th Edition. Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, Philadelphia, PA, USA, 569-604 (2008)
4. Prato R, Tafuri S, Fortunato F, Martinelli D. Why it is still important that countries know the burden of pneumococcal disease. Hum. Vaccin. 6(11), 42-45 (2010)
5. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol. Rec. 85(43), 434-436 (2010)
6. Michel JP, Chidiac C, Grubeck- Loebenstein B, et al. Advocating vaccination of adults aged 60 years and older in Western Europe: statement by the Joint Vaccine Working Group of the European Union Geriatric Medicine Society and the International Association of Gerontology and Geriatrics-European Region. Rejuvenation Res. 12(2), 127-135 (2009)
7. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin. Respir. Crit. Care Med. 30(2), 189-209 (2009)
8. Kyaw MH, Rose CE, Fry AM et al; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J. Infect. Dis. 192(3), 377-386 (2005) (Pubitemid 41023115)
9. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998- 2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin. Infect. Dis. 49(2), 205-212 (2009)
10. Klemets P, Lyytikäinen O, Ruutu P, Ollgren J, Nuorti J. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect. Dis. 8, 96 (2008)
11. Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 46(RR-8), 1-24 (1997)
12. Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedule - United States, 2002-2003. MMWR Morb. Mortal. Wkly Rep. 51(40), 904-908 (2002)
13. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR Morb. Mortal. Wkly Rep. 59(RR11), 1-18 (2010)
14. Klemets P, Lyytikäinen O, Ruutu P, et al. Risk of invasive pneumococcal infections among working age adults with asthma. Thorax 65(8), 698-702 (2010)
15. Michel J-P, Gusmano M, Blank PR, Philp I. Vaccination and healthy ageing, how to make life-course vaccination a successful public health strategy. Eur. Geriatr. Med. 1(3), 155-165 (2010)
16. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 22(8), 927-946 (2004) (Pubitemid 38228353)
17. Sjöström K, Spindler C, Ortqvist A, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin. Infect. Dis. 42(4), 451-459 (2006) (Pubitemid 43202515)
18. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr. Opin. Pulm. Med. 16(3), 217-225 (2010)
19. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J. Infect. Dis. 187(9), 1424-1432 (2003) (Pubitemid 36549688)
20. Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin. Infect. Dis. 51(6), 692-699 (2010)
21. Pletz MW, Welte T, Klugman KP. The paradox of pneumococcal serotypes: highly invasive does not mean highly lethal. Eur. Respir. J. 36(4), 712-713 (2010)
22. Alanee SR, McGee L, Jackson D, et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin. Infect. Dis. 45(1), 46-51 (2007) (Pubitemid 46984614)
23. Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 6(5), e1000081 (2009)
24. Ardanuy C, Tubau F, Pallares R, et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin. Infect. Dis. 48(1), 57-64 (2009)
25. Pilishvili T, Lexau C, Farley MM et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201(1), 32-41 (2010)
26. Vestrheim DF, Høiby EA, Bergsaker MR, et al. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine 28(10), 2214-2221 (2010)
27. Rodenburg GD, de Greeff SC, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, The Netherlands. Emerg. Infect. Dis. 16(5), 816-823 (2010)
28. Rozenbaum MH, Boersma C, Postma MJ, Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Exp. Rev. Vaccines 10(2), 187-199 (2011)
29. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin. Infect. Dis. 47(8), 989-996 (2008)
30. Greenberg D. The shifting dynamics of pneumococcal invasive disease after the introduction of the pneumococcal 7-valent conjugated vaccine: toward the new pneumococcal conjugated vaccines. Clin. Infect. Dis. 49(2), 213-215 (2009)
31. Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J. Infect. Dis. 193(11), 1487-1494 (2006) (Pubitemid 43794576)
32. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 28(26), 4249-4259 (2010)
33. Croucher NJ, Harris SR, Fraser C, et al. Rapid pneumococcal evolution in response to clinical interventions. Science 331(6016), 430-434 (2011)
34. Veenhoven R, Bogaert D, Uiterwaal C, et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 361(9376), 2189-2195 (2003) (Pubitemid 36782552)
35. Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin. Infect. Dis. 49(2), e23-e29 (2009)
36. Imöhl M, Reinert RR, van der Linden M. Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states. Int. J. Med. Microbiol. 300(4), 237-247 (2010)
37. Imöhl M, Reinert RR, Ocklenburg C, van der Linden M. Association of serotypes of Streptococcus pneumoniae with age in invasive pneumococcal disease. J. Clin. Microbiol. 48(4), 1291-1296 (2010)
38. Tsigrelis C, Tleyjeh IM, Lahr BD, Nyre LM, Virk A, Baddour LM. Trends in invasive pneumococcal disease among older adults in Olmsted County, Minnesota. J. Infect. 59(3), 188-193 (2009)
39. Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 125(3), 429-436 (2010)
40. Hsu KK, Shea KM, Stevenson AE, Pelton SI; Massachusetts Department of Public Health. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr. Infect. Dis. J. 29(4), 289-293 (2010)
41. Hanage WP, Huang SS, Lipsitch M, et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J. Infect. Dis. 195, 347-352 (2007) (Pubitemid 46146111)
42. Hanage WP. Serotype-specific problems associated with pneumococcal conjugate vaccination. Future Microbiol. 3(1), 23-30 (2010) (Pubitemid 351385948)
43. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin. Respir. Crit. Care Med. 30(2), 210-238 (2009)
44. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 374(9700), 1543-1556 (2009)
45. Imöhl M, Reinert RR, van der Linden M. Adult invasive pneumococcal disease between 2003 and 2006 in North-Rhine Westphalia, Germany: serotype distribution before recommendation for general pneumococcal conjugate vaccination for children <2 years of age. Clin. Microbiol. Infect. 15(11), 1008-1012 (2009)
46. Imöhl M, Reinert RR, van der Linden M. Serotype-specific penicillin resistance of Streptococcus pneumoniae in Germany from 1992 to 2008. Int. J. Med. Microbiol. 300(5), 324-330 (2010)
47. Trotter CL, Waight P, Andrews NJ, et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996-2006. J. Infect. 60(3), 200-208 (2010)
48. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 23(1), CD000422 (2008)
49. Moberley S, Krause V, Cook H, et al. Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal polysaccharide vaccine program in indigenous adults in the Northern Territory of Australia. Vaccine 28(11), 2296-2301 (2010)
50. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 180(1), 48-58 (2009)
51. Forrester HL, Jahnigan DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high risk population. Am. J. Med. 83, 435-430 (1987)
52. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann. Intern. Med. 108(5), 653-657 (1988)
53. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325(21), 1453-1460 (1991)
54. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 270(15), 1826-1831 (1993) (Pubitemid 23301436)
55. Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched casecontrol study. Arch. Intern. Med. 155(21), 2336-2240 (1995)
56. Benin AL, O'Brien KL, Watt JP, et al. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. J. Infect. Dis. 188(1), 81-89 (2003) (Pubitemid 36829746)
57. Jackson LA, Neuzil KM, Yu O et al; Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med. 348(18), 1747-1755 (2003) (Pubitemid 36514705)
58. Hedlund J, Christenson B, Lundbergh P, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine 21(25-26), 3906-3911 (2003) (Pubitemid 37345133)
59. Andrews RM, Counahan ML, Hogg GG, McIntyre PB. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine 23(2), 132-138 (2004) (Pubitemid 39505081)
60. Dominguez A, Salleras L, Fedson DS, et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin. Infect. Dis. 40(9), 1250-1257 (2005) (Pubitemid 40570233)
61. Vila-Corcoles A, Ochoa-Gondar O, Hospital I et al; EVAN Study Group. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin. Infect. Dis. 43(7), 860-868 (2006) (Pubitemid 44435513)
62. Singleton RJ, Butler JC, Bulkow LR, et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. Vaccine 25(12), 2288-2295 (2007) (Pubitemid 46227693)
63. Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch. Intern. Med. 167(18), 1938-1943 (2007) (Pubitemid 47606632)
64. Mooney JD, Weir A, McMenamin J, et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect. Dis. 8, 53 (2008)
65. Spindler C, Hedlund J, Jasir A, Normark BH, Ortqvist A. Effects of a large-scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden. Vaccine 26(43), 5541-5546 (2008)
66. Vila-Corcoles A, Salsench E, Rodriguez- Blanco T, et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 27(10), 1504-1510 (2009)
67. Vila-Corcoles A, Ochoa-Gondar O, Guzmn JA et al.; EPIVAC Study Group. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect. Dis. 10, 73 (2010)
68. Fedson DS. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: another view of the evidence. Lancet Infect. Dis. 3, 272-273 (2003)
69. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 351(9100), 399-403 (1998) (Pubitemid 28064163)
70. Honkanen PO, Keistinen T, Miettinen L, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 17(20-21), 2493-2500 (1999) (Pubitemid 29314440)
71. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 61(3), 189-195 (2006)
72. Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 340, c1004 (2010)
73. Dominguez A, Izquierdo C, Salleras L et al.; Working Group for the Study of Prevention of CAP in the Elderly. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur. Respir. J. 36(3), 608-614 (2010)
74. Skull SA, Andrews RM, Byrnes GB, et al. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: Benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine 25, 4634-4640 (2007)
75. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch. Intern. Med. 159(20), 2437-2442 (1999) (Pubitemid 29526772)
76. Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with communityacquired pneumonia. Clin. Infect. Dis. 42(8), 1093-1101 (2006)
77. Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin. Infect. Dis. 51(1), 15-22 (2010)
78. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 17(Suppl.), S91-S93 (1999) (Pubitemid 29366942)
79. Hung IF, Leung AY, Chu DW, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin. Infect. Dis. 51(9), 1007-1016 (2010)
80. Fedson DS. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness. Semin. Respir. Infect. 8, 285-293 (1993) (Pubitemid 24218424)
81. Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J. Infect. Dis. 201(4), 516-524 (2010)
82. Manoff SB, Liss C, Caulfield MJ, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years. J. Infect. Dis. 201(4), 525-533 (2010)
83. Musher DM, Sampath R, Rodriguez- Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin. Inf. Dis. 52(5), 633-640 (2011)
84. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin. Microbiol. Rev. 16, 308-318 (2003) (Pubitemid 36519814)
85. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect. Dis. 7, 597-606 (2007) (Pubitemid 47268225)
86. Nichol KL. Pneumococcal vaccination and revaccination in the elderly population. J. Infect. Dis. 201(5), 659-661 (2010)
87. Törling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 22(1), 96-103 (2003) (Pubitemid 37357156)
88. de Roux A, Schmöle-Thoma B, Schmöele- Thoma B, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin. Infect. Dis. 46(7), 1015-1023 (2008) (Pubitemid 351589866)
89. Väkeväinen M, Soininen A, Lucero M et al.; ARIVAC Consortium. Serotypespecific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J. Pediatr. 157(5), 778-783 (2010)
90. Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J. Infect. Dis. 201(10), 1570-1579 (2010)
91. Hammitt LL, Bulkow LR, Singleton RJ, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 9(12), 2287-2295 (2011)
92. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 281(3), 243-248 (1999) (Pubitemid 29058113)
93. Walker FJ, Singleton RJ, Bulkow LR, Strikas RA, Butler JC. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clin. Infect. Dis. 40(12), 1730-1735 (2005) (Pubitemid 40799939)
94. Weinberger DM, Dagan R, Givon-Lavi N, Regev-Yochay G, Malley R, Lipsitch M. Epidemiologic evidence for serotypespecific acquired immunity to pneumococcal carriage. J. Infect. Dis. 197(11), 1511-1518 (2008) (Pubitemid 351706480)
95. Baxendale HE, Keating SM, Johnson M, Southern J, Miller E, Goldblatt D. The early kinetics of circulating pneumococcalspecific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine 28(30), 4763-4770 (2010)
96. Baxendale HE, Johnson M, Keating SM, et al. Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination. Vaccine 28(42), 6915-6922 (2010)
97. Scott DA, Komjathy SF, Hu BT, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25(33), 6164-6146 (2007)
98. Scott D, Ruckle J, Dar M, Baker S, Kondoh H, Lockhart S. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr. Int. 50(3), 295-299 (2008) (Pubitemid 351781510)
99. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin. Infect. Dis. 49(9), 1318-1325 (2009)
100. Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J. Infect. Dis. 198(7), 1019-1027 (2008)
101. Miernyk KM, Butler JC, Bulkow LR, et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55-70 years of age. Clin. Infect. Dis. 49(2), 241-248 (2009)
102. Dransfield MT, Nahm MH, Han MK et al.; COPD Clinical Research Network. Superior immune response to proteinconjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 180(6), 499-505 (2009)
103. Ridda I, Macintyre CR, Lindley R, et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 27(10), 1628-1636 (2009)
104. Jackson LA, Neuzil KM, Nahm MH, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharideprotein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 25(20), 4029-4037 (2007) (Pubitemid 46616998)
105. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 28(31), 4955-4960 (2010)
106. File TM, Marrie TJ. Burden of communityacquired pneumonia in North American adults. Postgrad. Med. 122(2), 130-141 (2010)
107. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax DOI:10.1136/thx. 2009.129502 (2010) (Epub ahead of print)
108. Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin. Infect. Dis. 31(2), 444-450 (2000) (Pubitemid 32289574)
109. Evers SM, Ament AJ, Colombo GL, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur. J. Clin. Microbiol. Infect. Dis. 26(8), 531-540 (2007) (Pubitemid 47106804)
110. Smith KJ, Zimmerman RK, Lin CJ, et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine 26(11), 1420-1431 (2008)
111. Smith KJ, Lee BY, Nowalk MP, Raymund M, Zimmerman RK. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine 28(48), 7620-7625 (2010)
112. Kawakami K, Ohkusa Y, Kuroki R, et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 28(43), 7063-7069 (2010)
113. Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine 27(36), 4891-4904 (2009)
114. Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann. Intern. Med. 138(12), 960-968 (2003)
115. Ament A, Fedson DS, Christie P. Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost-effective. Clin. Infect. Dis. 33, 2078-2079 (2001) (Pubitemid 33152406)
116. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part II. A Cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur. J. Epidemiol. 19(4), 365-375 (2004) (Pubitemid 39005436)
117. Merito M, Giorgi Rossi P, Mantovani J, Curtale F, Borgia P, Guasticchi G. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy. Vaccine 25(3), 458-465 (2007) (Pubitemid 44873149)
118. Fedson DS. Influenza and pneumococcal vaccination of the elderly: newer vaccines and prospects for clinical benefits at the margin. Prev. Med. 23(5), 751-755 (1994) (Pubitemid 24377902)
119. van Assen S, Elkayam O, Agmon-Levin N, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Autoimmun. Rev. 10(6), 341-352 (2011)
120. Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb. Mortal. Wkly Rep. 59(34), 1102-1106 (2010)
121. Bonanni P, Boccalini S, Bechini A. The expected impact of new vaccines and vaccination policies. J. Public Health 16(4), 253-259 (2008)
122. Wahid ST, Nag S, Bilous RW, Marshall SM, Robinson AC. Audit of influenza and pneumococcal vaccination uptake in diabetic patients attending secondary care in the Northern Region. Diabet. Med. 18(7), 599-603 (2001) (Pubitemid 32823087)
123. Gavazzi G, Wazieres B, Lejeune B, Rothan-Tondeur M. Influenza and pneumococcal vaccine coverages in geriatric health care settings in France. Gerontology 53(6), 382-387 (2007) (Pubitemid 351664663)
124. Delelis-Fanien AS, Seite F, Priner M, Paccalin M. Vaccine coverage against influenza and pneumococcal infections in patients aged 65 and over: a survey on 299 outpatients. Rev. Med. Interne 30(8), 656-660 (2009)
125. Tiv M, Clinard F, Guthmann JP, et al. Pneumococcal and tetanus vaccination coverage in residents of nursing homes for eldery people in Burgundy and Franche- Comté regions, France, 2009. BEH 4, 25-28 (2010)
126. Martinelli D, Tafuri S, Caputi G, et al. Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: survey on coverage rate among elderly and chronic patients. Am. J. Infect. Control. 38(4), e8-e15 (2010)
127. Bossuyt N, Van Casteren V. Pneumococcal vaccination coverage in elderly people in Belgium. Arch. Public Health 63, 185-198 (2005)
128. Mereckiene J, Cotter S, O'Donnell J, Igoe D, O'Hora D, O'Flanagan D. Telephone survey to assess uptake of seasonal, pandemic influenza and pneumococcal vaccines in Ireland during the 2009/10 influenza season. Presented at: EuroVaccine Congress. Stockholm, Sweden, 10 December 2010
129. Santibanez TA, Zimmerman RK, Nowalk MP, Jewell IK, Bardella IJ. Physician attitudes and beliefs associated with patient pneumococcal polysaccharide vaccination status. Ann. Fam. Med. 2(1), 41-48 (2004) (Pubitemid 39318018)
130. Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am. J. Med. 121(7 Suppl.), S28-S35 (2008) (Pubitemid 351876196)
131. Kyaw MH, Greene CM, Schaffner W, et al. Adults with invasive pneumococcal disease - missed opportunities for vaccination. Am. J. Prev. Med. 32(4), 286-292 (2006) (Pubitemid 44354003)
132. Fedson DS, Houck P, Bratzler D. Hospital based influenza and pneumococcal vaccination: Sutton's Law applied to prevention. Infect. Control Hosp. Epidemiol. 21(11), 692-699 (2000)
133. Middleton DB, Lin CJ, Smith KJ, et al. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients. Infect. Control. Hosp. Epidemiol. 29(5), 385-394 (2008) (Pubitemid 351589971)
134. Rijkers GT, van Mens SP, van Velzen-Blad H. What do the next 100 years hold for pneumococcal vaccination? Expert Rev. Vaccines 9(11), 1241-1244 (2010)
135. Vila-Corcoles A, Ochoa-Gondar O, Ester F, et al. Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up. BMC Public Health 6, 231 (2006)
136. European Centre for Disease Prevention and Control (ECDC). Surveillance Report. Annual Epidemiological Report On Communicable Diseases in Europe 2010 www.ecdc.europa.eu/en/publications/Publications/1011-SUR-Annual-Epidemiological- Report-on-Communicable-Diseases-in-Europe.pdf
137. Centers for Disease Control and Prevention (CDC). Active Bacterial Core Surveillance Report, Emerging Infections Program Network Streptococcus pneumoniae, 2009 (2010) www.cdc.gov/abcs/reports-findings/survreports/spneu09. pdf
138. Centre National de Référence des pneumocoques. Rapport diactivité 2009 www.invs.sante.fr/surveillance/cnr/rapport-cnrp-2009.pdf
139. Zhang N, Pebody R. Pneumococcal polysaccharide vaccine uptake. Report 2006/07, England. Health Protection Agency, London, UK (2007) www.hpa.org.uk/web/HPAwebFile/HPAweb-C/1194947383417
140. Begum F, Pebody R. Annual pneumococcal polysaccharide vaccine uptake in 65 years old and over for England. Influenza immunization uptake monitoring programme. Department of Health and Health Protection Agency, London, UK (2008) www.hpa.org.uk/web/HPAwebFile/HPAweb-C/1216711845635
141. Enquête de santé par interview, Belgique 2008. www.wiv-isp.be/epidemio/epifr/CROSPFR/HISFR/his08fr/r2/9.la%20 vaccination-r2.pdf
142. Vorausberechnete Bevölkerungsstruktur für Österreich 2010-2075 laut Hauptszenario www.statistik.at/web-de/statistiken/bevoelkerung/ demographische-prognosen/bevoelkerungsprognosen/027308.html
143. Statistics Belgium www.statbel.fgov.be
144. Hvad er Danmarks Statistikbank www.statistikbanken.dk/statbank5a/default. asp?w=1280
145. Statistics Finland www.stat.fi
146. Projections de population active à l'horizon 2050 www.cor-retraites.fr/IMG/pdf/doc-374.pdf
147. koordinierte Bevölkerungs- Vorausberechnung www.destatis.de/ jetspeed/portal/cms/Sites/destatis/Internet/DE/Presse/pk/2006/ Bevoelkerungsentwicklung/Annahmen-und-Ergebnisse,property=file.pdf
148. Hellenic Statistical Authority (ELSTAT). Statistical themes: de facto population www.statistics.gr/portal/page/portal/ESYE/PAGE-themes?p-param=A1604
149. Statistics Iceland. Population www.statice.is/Statistics/Population
150. Central Statistics Office Ireland. Population www.cso.ie/statistics/ Population.htm
151. Italian National Institute of Statistics (ISTAT). Population http://en.istat.it/popolazione/
152. Statistics Netherlands. Population www.cbs.nl/en-GB/menu/themas/ bevolking/cijfers/default.htm
153. Statistics Norway. Focus on Population www.ssb.no/befolkning-en/
154. In the spotlight demographic change: challenge or opportunity? http://epp.eurostat.ec.europa.eu/cache/ITY-OFFPUB/KS-CD-07-001-SPOT/EN/ KS-CD-07-001-SPOT-EN.PDF
155. National Statistics Institute (INE) Short-term population projections. 2008-2018 www.ine.es/jaxi/menu.do?type=pcaxis&pa th=%2Ft20%2Fp269%2F2008- 2018&file=pcaxis&L=
156. Statistics Sweden. Population www.scb.se/Pages/SubjectArea-2442. aspx
157. Swiss Federal Statistical Office. Population www.bfs.admin.ch/bfs/portal/ en/index/themen/01.html
158. Office for National Statistics. National Population Projections www.statistics.gov.uk/statbase/Product. asp&vlnk=8519